Company intelligence / Profile preview

Ten30 Biosciences

Alameda, California, United States

Ownership: Private
Development stage: Other

Overview

Ten30 Biosciences is pioneering a platform for orally available small molecule protein degraders targeting previously undruggable proteins in hematologic, neurodegenerative, inflammatory, and cancer indications. The company is currently in preclinical stages; no clinical results have been disclosed as of the latest available information.

Therapeutic areas: OncologyHematologyNeurologyImmunology
Modalities: Small moleculeProtein degrader
Industry: Biotech

Beyond the preview

Go deeper on Ten30 Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ten30 Biosciences.

Explore the full profile